Henry Schein helps raise $10,000 for AAEP Foundation
Henry Schein, Inc. demonstrated its commitment to supporting the education of the next generation of veterinary practitioners by spearheading a fundraising effort that raised $10,000 for the American Association of Equine Practitioners (AAEP) Foundation, a nonprofit organization that serves as the charitable arm of the AAEP, according to a release. The check was presented to Jeffrey T. Berk, VMD, Chairman of the AAEP Foundation Advisory Council, at the 62nd annual AAEP Convention held in Orlando, Fla. Henry Schein joined supplier partners Zoetis and Neogen to support the AAEP Foundation’s “Collegiate Challenge” fundraiser by matching $10 donations made by convention attendees. In total, the company donated $10,000 to the AAEP Foundation, which raised more than $36,000 through the challenge to support AAEP’s student chapter activity; courses on dentistry, podiatry, and horse handling; and continuing education programs.
EEG releases updated recommendations on the diagnosis and treatment of equine metabolic syndrome
The Equine Endocrinology Group (EEG) has released updated written recommendations on the diagnosis and treatment of equine metabolic syndrome (EMS), according to a release. The recommendations also include information on the detection, testing, assessment, and management of EMS. “These guidelines are important because they provide the most up to date, concise, accurate information in a reference guide that veterinarians can easily carry and review,” says Steve Grubbs, DVM, PhD, DACVIM, equine technical manager for Boehringer Ingelheim Vetmedica, Inc. (BIVI). EMS is characterized by three main features: obesity or regional adiposity, insulin resistance and a high risk for laminitis. EEG updates their recommendations every two years, The EEG also publishes recommendations for pituitary pars immune dysfunction (PPID), another endocrine disorder. The recommendations for EMS and PPID can be found on the EEG web site: http://sites.tufts.edu/equineendogroup.
Merck Animal Health unveils new Flu Avert® I.N. Intranasal Applicator
Veterinarians now have access to a proprietary new intranasal applicator for administering the Flu Avert I.N. equine influenza vaccine, according to Merck Animal Health. The applicator, which was introduced during the annual meeting of the American Association of Equine Practitioners, not only makes vaccination easier for the horse and veterinarian, but it also delivers enhanced mucosal coverage within the nasal cavity. “Flu Avert is special, in part, because of its unique intranasal application, and veterinarians have long recognized the benefits of Flu Avert for its exceptional influenza protection,” says Bryant Craig, D.V.M., Merck Animal Health equine veterinary technical services manager. “However, previous applicators could be difficult to use as many horses didn’t appreciate the 6-inch cannula being inserted into their nasal cavity.” The new applicator, which is 1-inch long, is administered from just inside the ventral nares and is hardly noticeable to the horse. It uniquely atomizes the vaccine into a very fine mist, delivering it in a much smaller particle size than with other applicators. This allows the vaccine to reach further into the nasal cavity and cover a broader area of the nasal and pharyngeal mucosa. The new applicator is available to veterinarians beginning in January 2017. For more information on Flu Avert I.N. and the new intranasal applicator, veterinarians are encouraged to contact their Merck Animal Health sales representative or call 1-800-521-5767.